-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $47

Benzinga·11/06/2026 11:01:57
Listen to the news
Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price target from $43 to $47.